Skip to main content
Equibles
RGNX logo

RGNX · REGENXBIO Inc. · Metrics

Track RGNX — free

Use RGNX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RGNX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.56 -0.17 (-1.95%) At close · Sep 10
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Aug 6, 2026

The latest filing no longer states the doubt (first flagged May 14, 2026).

View the 10-Q filed Aug 6, 2026
Market Cap
$576.30M
Shares
66.01M

RGNX metrics

66 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$8.56
Market cap
$576.30M

Price action

20 metrics
Price change (1W)
-9.1%
Price change (30D)
-18.0%
Price change (3M)
+42.4%
Price change (6M)
-6.9%
Price change (YTD)
-39.4%
Price change (1Y)
-11.7%
Trailing year
Price change (5Y)
-74.0%
52-week high
$15.98
52-week low
$5.65
Change from 52-week high
-45.4%
Change from 52-week low
+54.5%
Annualized volatility
93.5%
Annualized volatility (3M)
104.1%
Beta
2.0
RSI (14D)
40.0
Price vs SMA 50
-19.6%
Price vs SMA 200
-15.3%
Avg volume (3M)
1.94M
Relative volume
0.7
Average dollar volume
$20.42M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
66.01M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.3×
reciprocal yield 30.3%
P / book
8.0
reciprocal yield 12.5%
FCF yield
-43.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-34.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
-94.1%
Trailing 12 months
Net margin
-112.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$164.15M
Net income (TTM)
−$196.43M
Trailing 12 months
Diluted EPS (TTM)
$-3.79
FCF margin
-143.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.02

Growth

11 metrics
Revenue growth YoY
+405.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$174.48M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.0%
Year over year · more shares
Revenue CAGR (3Y)
+14.8%
Revenue CAGR (5Y)
+2.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-273.7%
Return on assets
-50.8%
Debt / equity
—
Current ratio
2.9
EBITDA (TTM)
−$148.78M
Free cash flow (TTM)
−$249.67M
Quick ratio
2.9
Interest coverage
-3.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$105.52M
Latest balance sheet
Cash & equivalents
$36.49M
Total assets
$386.62M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$246.67M
Capital expenditures (TTM)
$2.99M
R&D (TTM)
$229.14M
SG&A (TTM)
—
Stock compensation (TTM)
$35.04M
R&D / revenue
131.3%
Stock compensation / revenue
20.1%

Ownership (13F)

3 metrics
13F filers
166
13F filer change QoQ
-14
Institutional ownership
65.0%

Short interest

3 metrics
Short interest
11.4%
Latest settlement · 4.9 days to cover
Days to cover
4.9d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
$231,150
Insider-sentiment score
79 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1590877 CUSIP 75901B107 13F (30d) 99 filings 99 filers Visit website Investor relations